The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic, according to ABC News.

The Hill reported that the FDA on Monday required pharmaceutical companies to warn patients and health care providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. The outlet identified the condition as non-arteritic anterior ischemic optic neuropathy, known as NAION, which it said is often referred to as an "eye stroke."

The Hill's report was written by Nathaniel Weixel. The portion of the story available describes NAION as a rare condition, but the summary does not explain its symptoms, how often it occurs, or what treatment is involved.

The two outlets describe the action in different terms. ABC News framed it as a warning about possible rare cases of vision loss already reported with these drugs, while The Hill framed it as a warning about a potential increased risk of a specific condition. Neither summary gives case counts, the agency's supporting data, or the exact wording of the new warning.

Both reports were published on Monday, and neither summary says when drug companies must add the warning to their product labels. The summaries available for this story also do not include the agency's reasoning for the action.

Sources: ABC News: FDA adds rare vision-loss warning to popular GLP-1 drugs; The Hill: FDA warns of rare ‘eye stroke’ risk from GLP-1 drugs.